The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
Abstract
CONTEXT: Studies have suggested that the use of rosiglitazone may be associated with an increased risk of serious cardiovascular events compared with other treatments for type 2 diabetes. OBJECTIVE: To determine if the risk of serious cardiovascular harm is increased by rosiglitazone compared with pioglitazone, the other thiazolidinedione marketed in the United States. DESIGN, SETTING, AND PATIENTS: Nationwide, observational, retrospective, inception cohort of 227,571 Medicare beneficiaries aged 65 years or older (mean age, 74.4 years) who initiated treatment with rosiglitazone or pioglitazone through a Medicare Part D prescription drug plan from July 2006-June 2009 and who underwent follow-up for up to 3 years after thiazolidinedione initiation. MAIN OUTCOME MEASURES: Individual end points of acute myocardial infarction (AMI), stroke, heart failure, and all-cause mortality (death), and composite end point of AMI, stroke, heart failure, or death, assessed using incidence rates by thiazolidinedione, attributable risk, number needed to harm, Kaplan-Meier plots of time to event, and Cox proportional hazard ratios for time to event, adjusted for potential confounding factors, with pioglitazone as reference. RESULTS: A total of 8667 end points were observed during the study period. The adjusted hazard ratio for rosiglitazone compared with pioglitazone was 1.06 (95% confidence interval [CI], 0.96-1.18) for AMI; 1.27 (95% CI, 1.12-1.45) for stroke; 1.25 (95% CI, 1.16-1.34) for heart failure; 1.14 (95% CI, 1.05-1.24) for death; and 1.18 (95% CI, 1.12-1.23) for the composite of AMI, stroke, heart failure, or death. The attributable risk for this composite end point was 1.68 (95% CI, 1.27-2.08) excess events per 100 person-years of treatment with rosiglitazone compared with pioglitazone. The corresponding number needed to harm was 60 (95% CI, 48-79) treated for 1 year. CONCLUSION: Compared with prescription of pioglitazone, prescription of rosiglitazone was associated with an increased risk of stroke, heart failure, and all-cause mortality and an increased risk of the composite of AMI, stroke, heart failure, or all-cause mortality in patients 65 years or older.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 1×
“The proportional hazards assumption was assessed using a test of weighted Schoenfeld residuals.(32) The number needed to harm was estimated using the attributable risk.”
MethodEffect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 4×
“We restricted the cohorts to the 110 950 patients who entered the study prior to the May 21, 2007, publication of the rosiglitazone meta-analysis by Nissen and Wolski.(1) Nearly identical results were obtained for the main analysis (eTable 1, available at http://www .”
BackgroundMethodResultInfluentialDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Zipes, D. P., & Wellens, H. J. J. (1998) · Circulation · doi:10.1161/01.cir.98.21.2334 · Cited by 2,744
Sudden Cardiac Death in the United States, 1989 to 1998
Zheng, Z.-J., Croft, J. B., Giles, W. H., & Mensah, G. A. (2001) · Circulation · doi:10.1161/hc4301.098254 · Cited by 1,596
Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors
Birman-Deych, E., Waterman, A. D., Yan, Y., Nilasena, D. S., Radford, M. J., & Gage, B. F. (2005) · Medical Care · doi:10.1097/01.mlr.0000160417.39497.a9 · Cited by 719
Lago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710
Kokotailo, R. A., & Hill, M. D. (2005) · Stroke · doi:10.1161/01.str.0000174293.17959.a1 · Cited by 709
Cited by
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016
Polycystic ovary syndrome: etiology, pathogenesis and diagnosis
Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.217 · Cited by 1,488
“By contrast, thiazolidinediones are associated with weight gain, fluid retention and heart failure, and rosiglitazone has been associated with an increased risk of myocardial infarction”
BackgroundType 2 diabetes mellitus in older adults: clinical considerations and management
Bellary, S., Kyrou, I., Brown, J. E., & Bailey, C. J. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00512-2 · Cited by 639
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
“Their conclusion was based on recent observational data (42, 43) and 2 meta-analyses by Nissen and Wolski (44, 45), as well as on increased understanding of the pharmacology of rosiglitazone (46).”
BackgroundNatural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
Wang, L., Waltenberger, B., Pferschy-Wenzig, E.-M., Blunder, M., Liu, X., Malainer, C., Blazevic, T., Schwaiger, S., Rollinger, J. M., Heiss, E. H., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.018 · Cited by 594
Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes
Soccio, R. E., Chen, E. R., & Lazar, M. A. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.005 · Cited by 518
Mitochondrial quality control in kidney injury and repair
Tang, C., Cai, J., Yin, X.-M., Weinberg, J. M., Venkatachalam, M. A., & Dong, Z. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00369-0 · Cited by 513
Page, R. L., O’Bryant, C. L., Cheng, D., Dow, T. J., Ky, B., Stein, C. M., Spencer, A. P., Trupp, R. J., & Lindenfeld, J. (2016) · Circulation · doi:10.1161/cir.0000000000000426 · Cited by 471
Thiazolidinediones: the forgotten diabetes medications
Lebovitz, H. E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1270-y · Cited by 388
Nyenwe, E. A., Jerkins, T. W., Umpierrez, G. E., & Kitabchi, A. E. (2011) · Metabolism · doi:10.1016/j.metabol.2010.09.010 · Cited by 343
Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring
Mitchell, J. D., Fergestrom, N., Gage, B. F., Paisley, R., Moon, P., Novak, E., Cheezum, M., Shaw, L. J., & Villines, T. C. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.051 · Cited by 320
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier
Divakaruni, A. S., Wiley, S. E., Rogers, G. W., Andreyev, A. Y., Petrosyan, S., Loviscach, M., Wall, E. A., Yadava, N., Heuck, A. P., Ferrick, D. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303360110 · Cited by 308
Diabetic nephropathy: diagnosis and treatment
Fineberg, D., Jandeleit-Dahm, K. A. M., & Cooper, M. E. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.184 · Cited by 295
Danaei, G., Rodríguez, L. A. G., Cantero, O. F., Logan, R., & Hernán, M. A. (2013) · Statistical Methods in Medical Research · doi:10.1177/0962280211403603 · Cited by 292
Sapieha, P., Stahl, A., Chen, J., Seaward, M. R., Willett, K. L., Krah, N. M., Dennison, R. J., Connor, K. M., Aderman, C. M., Liclican, E., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001571 · Cited by 252
Kung, J., & Henry, R. R. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.691963 · Cited by 198
Lepore, J. J., Olson, E., Demopoulos, L., Haws, T., Fang, Z., Barbour, A. M., Fossler, M., Davila-Roman, V. G., Russell, S. D., & Gropler, R. J. (2016) · JACC: Heart Failure · doi:10.1016/j.jchf.2016.01.008 · Cited by 165
Number needed to treat (NNT) in clinical literature: an appraisal
Mendes, D., Alves, C., & Batel-Marques, F. (2017) · BMC Medicine · doi:10.1186/s12916-017-0875-8 · Cited by 169
Bates, B. A., Akhabue, E., Nahass, M. M., Mukherjee, A., Hiltner, E., Rock, J., Wilton, B., Mittal, G., Visaria, A., Rua, M., et al. (2023) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.122.009078 · Cited by 118
Xu, Y., Yu, T., Ma, G., Zheng, L., Jiang, X., Yang, F., Wang, Z., Li, N., He, Z., Song, X., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.62556 · Cited by 110
Coronary Artery Calcium and Long-Term Risk of Death, Myocardial Infarction, and Stroke
Mitchell, J. D., Paisley, R., Moon, P., Novak, E., & Villines, T. C. (2018) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2017.09.003 · Cited by 107
Saremi, A., Schwenke, D. C., Buchanan, T. A., Hodis, H. N., Mack, W. J., Banerji, M., Bray, G. A., Clement, S. C., Henry, R. R., Kitabchi, A. E., et al. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300346 · Cited by 101
Paneni, F., & Lüscher, T. F. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.015 · Cited by 83
Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
Consoli, A., & Formoso, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12101 · Cited by 76
AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
Lu, Q., Li, X., Liu, J., Sun, X., Rousselle, T., Ren, D., Tong, N., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181995 · Cited by 69
Pharmacological treatment of diabetes in older people
Valencia, W. M., & Florez, H. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12362 · Cited by 62
Pioglitazone attenuates valvular calcification induced by hypercholesterolemia
Chu, Y., Lund, D. D., Weiss, R. M., Brooks, R. M., Doshi, H., Hajj, G. P., Sigmund, C. D., & Heistad, D. D. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300794 · Cited by 49
Sodium glucose co-transporter 2 inhibitors and heart failure.
Ghosh, R. K., Ghosh, G. C., Gupta, M., Bandyopadhyay, D., Akhtar, T., Deedwania, P., Lavie, C. J., Fonarow, G. C., & Aneja, A. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.08.038 · Cited by 41
Khera, R., Schuemie, M. J., Lu, Y., Ostropolets, A., Chen, R., Hripcsak, G., Ryan, P. B., Krumholz, H. M., & Suchard, M. A. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057977 · Cited by 37
Desai, R. J., Levin, R., Lin, K. J., & Patorno, E. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016906 · Cited by 29
Metadata
- Authors
- Graham, D. J., Ouellet-Hellstrom, R., MaCurdy, T. E., Ali, F., Sholley, C., Worrall, C., & Kelman, J. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2010-07-28
- Volume
- 304
- Issue
- 4
- Pages
- 411
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1998418707
- Cited by
- 512
- References
- 32
- FWCI
- 55.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.